Adverse events associated with smallpox vaccination in the United States, January-October 2003
- PMID: 16333009
- DOI: 10.1001/jama.294.21.2734
Adverse events associated with smallpox vaccination in the United States, January-October 2003
Abstract
Context: On January 24, 2003, the US Department of Health and Human Services (DHHS) implemented a preparedness program in which smallpox (vaccinia) vaccine was administered to federal, state, and local volunteers who might be first responders during a bioterrorism event.
Objective: To describe results from the comprehensive DHHS smallpox vaccine safety monitoring and response system.
Design, setting, and participants: Descriptive study of adverse event reports from the DHHS smallpox vaccine safety monitoring and response system received between January 24 and October 31, 2003, through the Vaccine Adverse Event Reporting System (VAERS) and the Centers for Disease Control and Prevention. A total of 37,901 volunteers in 55 jurisdictions received at least 1 dose of smallpox vaccine.
Main outcome measures: Number of vaccinations administered and description of adverse events and reporting rates.
Results: A total of 38,885 smallpox vaccinations were administered, with a take rate of 92%. VAERS received 822 reports of adverse events following smallpox vaccination (overall reporting rate, 217 per 10,000 vaccinees). A total of 590 adverse events (72%) were reported within 14 days of vaccination. Nonserious adverse events (n = 722) included multiple signs and symptoms of mild and self-limited local reactions. One hundred adverse events (12%) were designated as serious, resulting in 85 hospitalizations, 2 permanent disabilities, 10 life-threatening illnesses, and 3 deaths. Among the serious adverse events, 21 cases were classified as myocarditis and/or pericarditis and 10 as ischemic cardiac events that were not anticipated based on historical data. Two cases of generalized vaccinia and 1 case of postvaccinial encephalitis were detected. No preventable life-threatening adverse reactions, contact transmissions, or adverse reactions that required treatment with vaccinia immune globulin were identified. Serious adverse events were more common among older revaccinees than younger first-time vaccinees.
Conclusions: Rigorous smallpox vaccine safety screening, educational programs, and older vaccinees may have contributed to low rates of preventable life-threatening adverse reactions. Other rare, clinically significant, or unexpected cardiac adverse events were detected by timely review of VAERS data and intensive clinical case investigation.
Comment in
-
Smallpox vaccinations and adverse events.JAMA. 2006 Apr 26;295(16):1897-8. doi: 10.1001/jama.295.16.1897-c. JAMA. 2006. PMID: 16639045 No abstract available.
Similar articles
-
Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions.MMWR Recomm Rep. 2006 Feb 3;55(RR-1):1-16. MMWR Recomm Rep. 2006. PMID: 16456528
-
Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).MMWR Recomm Rep. 2003 Apr 4;52(RR-7):1-16. MMWR Recomm Rep. 2003. PMID: 12710832
-
Smallpox vaccination and adverse reactions. Guidance for clinicians.MMWR Recomm Rep. 2003 Feb 21;52(RR-4):1-28. MMWR Recomm Rep. 2003. PMID: 12617510
-
Smallpox vaccine: contraindications, administration, and adverse reactions.Am Fam Physician. 2003 Sep 1;68(5):889-96. Am Fam Physician. 2003. PMID: 13678138 Review.
-
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.Pediatr Infect Dis J. 2004 Apr;23(4):287-94. doi: 10.1097/00006454-200404000-00002. Pediatr Infect Dis J. 2004. PMID: 15071280 Review.
Cited by 41 articles
-
Modulation of Cell Surface Receptor Expression by Modified Vaccinia Virus Ankara in Leukocytes of Healthy and HIV-Infected Individuals.Front Immunol. 2020 Sep 8;11:2096. doi: 10.3389/fimmu.2020.02096. eCollection 2020. Front Immunol. 2020. PMID: 33013882 Free PMC article.
-
Vaccination against the Epstein-Barr virus.Cell Mol Life Sci. 2020 Nov;77(21):4315-4324. doi: 10.1007/s00018-020-03538-3. Epub 2020 May 4. Cell Mol Life Sci. 2020. PMID: 32367191 Free PMC article. Review.
-
Replication-inducible vaccinia virus vectors with enhanced safety in vivo.PLoS One. 2020 Apr 2;15(4):e0230711. doi: 10.1371/journal.pone.0230711. eCollection 2020. PLoS One. 2020. PMID: 32240193 Free PMC article.
-
Differential Response Following Infection of Mouse CNS with Virulent and Attenuated Vaccinia Virus Strains.Vaccines (Basel). 2019 Feb 12;7(1):19. doi: 10.3390/vaccines7010019. Vaccines (Basel). 2019. PMID: 30759813 Free PMC article.
-
Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?Viruses. 2017 Oct 29;9(11):318. doi: 10.3390/v9110318. Viruses. 2017. PMID: 29109380 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical